Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI.

Zhang Y, Udayakumar D, Cai L, Hu Z, Kapur P, Kho EY, Pavía-Jiménez A, Fulkerson M, de Leon AD, Yuan Q, Dimitrov IE, Yokoo T, Ye J, Mitsche MA, Kim H, McDonald JG, Xi Y, Madhuranthakam AJ, Dwivedi DK, Lenkinski RE, Cadeddu JA, Margulis V, Brugarolas J, DeBerardinis RJ, Pedrosa I.

JCI Insight. 2017 Aug 3;2(15). pii: 94278. doi: 10.1172/jci.insight.94278. [Epub ahead of print]

2.

Evidence-Based Cancer Imaging.

Shinagare AB, Khorasani R.

Korean J Radiol. 2017 Jan-Feb;18(1):107-112. doi: 10.3348/kjr.2017.18.1.107. Epub 2017 Jan 5. Review.

3.

Oncology Gold Standard™ practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma.

Authors OGS RCC Group (in Alphabetical Order) Coordinating Committee, Batra U, Parikh PM, Prabhash K, Tongaonkar HB; and Expert Group Members, Chibber P, Dabkara D, Deshmukh C, Ghadyalpatil N, Hingmire S, Joshi A, Raghunath SK, Rajappa S, Rajendranath R, Rawal SK, Singh M, Singh R, Somashekhar SP, Sood R.

South Asian J Cancer. 2016 Oct-Dec;5(4):167-175. doi: 10.4103/2278-330X.189933.

4.

Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.

Feng F, Cheng Q, Yang L, Zhang D, Ji S, Zhang Q, Lin Y, Li F, Xiong L, Liu C, Jiang X.

Oncotarget. 2017 Jan 17;8(3):5349-5360. doi: 10.18632/oncotarget.14146.

5.

Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?

Zaffuto E, Karakiewicz PI, Capitanio U.

Ann Transl Med. 2016 Aug;4(15):291. doi: 10.21037/atm.2016.06.25. No abstract available.

6.

Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis.

Wang H, Man L, Li G, Huang G, Wang J.

Onco Targets Ther. 2016 Jun 8;9:3423-32. doi: 10.2147/OTT.S100706. eCollection 2016. Review.

7.

CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma.

Motoshima T, Komohara Y, Horlad H, Tsukamoto H, Fujita M, Saito Y, Tanoue K, Kasejima Y, Sugiyama Y, Kawano Y, Nishimura Y, Takeya M, Eto M.

Oncol Lett. 2016 Mar;11(3):1911-1916. Epub 2016 Jan 20.

8.

Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine.

Wittke S, Baxmann S, Fahlenkamp D, Kiessig ST.

Onco Targets Ther. 2016 Jan 27;9:523-37. doi: 10.2147/OTT.S92182. eCollection 2016.

9.

Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression.

Brooks SA, Khandani AH, Fielding JR, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, Smith AB, Nielsen ME, Parker JS, Lalush DS, Rathmell WK.

Clin Cancer Res. 2016 Jun 15;22(12):2950-9. doi: 10.1158/1078-0432.CCR-15-2115. Epub 2016 Jan 19.

10.

Renal cell carcinoma risk is associated with the interactions of APOE, VHL and MTHFR gene polymorphisms.

Lv C, Bai Z, Liu Z, Luo P, Zhang J.

Int J Clin Exp Pathol. 2015 May 1;8(5):5781-6. eCollection 2015.

11.

Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics.

Mirza Z, Schulten HJ, Farsi HM, Al-Maghrabi JA, Gari MA, Chaudhary AG, Abuzenadah AM, Al-Qahtani MH, Karim S.

PLoS One. 2015 Mar 19;10(3):e0119765. doi: 10.1371/journal.pone.0119765. eCollection 2015.

12.

The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.

Tzogani K, Skibeli V, Westgaard I, Dalhus M, Thoresen H, Slot KB, Damkier P, Hofland K, Borregaard J, Ersbøll J, Salmonson T, Pieters R, Sylvester R, Mickisch G, Bergh J, Pignatti F.

Oncologist. 2015 Feb;20(2):196-201. doi: 10.1634/theoncologist.2014-0177. Epub 2015 Jan 23. Review.

13.

Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.

Hatipoglu G, Hock SW, Weiss R, Fan Z, Sehm T, Ghoochani A, Buchfelder M, Savaskan NE, Eyüpoglu IY.

Cancer Sci. 2015 Feb;106(2):160-70. doi: 10.1111/cas.12580. Epub 2015 Feb 15.

14.

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines.

Davidson BA, Rubatt JM, Corcoran DL, Teoh DK, Bernardini MQ, Grace LA, Soper WJ, Berchuck A, Siamakpour-Reihani S, Chen W, Owzar K, Murphy SK, Secord AA.

Front Oncol. 2014 Jun 20;4:163. doi: 10.3389/fonc.2014.00163. eCollection 2014.

15.

CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.

Ieranò C, Santagata S, Napolitano M, Guardia F, Grimaldi A, Antignani E, Botti G, Consales C, Riccio A, Nanayakkara M, Barone MV, Caraglia M, Scala S.

Cell Death Dis. 2014 Jul 3;5:e1310. doi: 10.1038/cddis.2014.269.

16.

Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy.

Wang L, Williamson SR, Wang M, Davidson DD, Zhang S, Baldridge LA, Du X, Cheng L.

Mol Cancer. 2014 Feb 26;13:39. doi: 10.1186/1476-4598-13-39.

17.

Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.

Pal K, Cao Y, Gaisina IN, Bhattacharya S, Dutta SK, Wang E, Gunosewoyo H, Kozikowski AP, Billadeau DD, Mukhopadhyay D.

Mol Cancer Ther. 2014 Feb;13(2):285-96. doi: 10.1158/1535-7163.MCT-13-0681. Epub 2013 Dec 10.

18.

Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.

Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK.

Cancer. 2014 Mar 1;120(5):711-21. doi: 10.1002/cncr.28493. Epub 2013 Nov 21.

19.

Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.

Koshiyama M, Matsumura N, Baba T, Yamaguchi K, Yoshioka Y, Konishi I.

Cancer Biol Ther. 2014 Jan;15(1):22-5. doi: 10.4161/cbt.26608. Epub 2013 Oct 21.

20.

Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma.

Santoni M, De Giorgi U, Iacovelli R, Conti A, Burattini L, Rossi L, Luca Burgio S, Berardi R, Muzzonigro G, Cortesi E, Amadori D, Cascinu S.

Br J Cancer. 2013 Oct 1;109(7):1755-9. doi: 10.1038/bjc.2013.522. Epub 2013 Sep 5.

Supplemental Content

Support Center